Free Newsletter
NIH expands list of approved ESC lines
As promised, the NIH approved 13 new embryonic stem cell lines for use in federally sponsored research work. The approval pushes past the demarcation line drawn by President George W. Bush more than eight years ago when he limited the use of federal dollars to a group of existing lines. That move forced researchers to carefully allocate the equipment and manpower used in the lab for federally sponsored or privately-backed ESC work. Story
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
